High-dose ketoconazole treatment in advanced prostatic cancer. 1988

S Scultéty, and J Oszlánczy, and I Faredin, and I Tóth
Department of Urology, University Medical School, Szeged, Hungary.

For purposes of testosterone suppression, high doses of ketoconazole were administered to 18 patients with advanced cancer of the prostate for an average of 6 months. A well-evaluable response was observed both objectively and subjectively. The blood levels of the steroid hormones were measured during the treatment period and it was found that testosterone biosynthesis was blocked. Mild gastrointestinal symptoms occurred in the minority of the cases, and administration of the drug had to be stopped in one case because of jaundice. The possibility of the use of smaller doses is being investigated, which may lead to the development of an alternative to the endocrine treatment methods.

UI MeSH Term Description Entries
D007654 Ketoconazole Broad spectrum antifungal agent used for long periods at high doses, especially in immunosuppressed patients. Nizoral,R-41400,R41,400,R41400,R 41400
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011374 Progesterone The major progestational steroid that is secreted primarily by the CORPUS LUTEUM and the PLACENTA. Progesterone acts on the UTERUS, the MAMMARY GLANDS and the BRAIN. It is required in EMBRYO IMPLANTATION; PREGNANCY maintenance, and the development of mammary tissue for MILK production. Progesterone, converted from PREGNENOLONE, also serves as an intermediate in the biosynthesis of GONADAL STEROID HORMONES and adrenal CORTICOSTEROIDS. Pregnenedione,Progesterone, (13 alpha,17 alpha)-(+-)-Isomer,Progesterone, (17 alpha)-Isomer,Progesterone, (9 beta,10 alpha)-Isomer
D011471 Prostatic Neoplasms Tumors or cancer of the PROSTATE. Cancer of Prostate,Prostate Cancer,Cancer of the Prostate,Neoplasms, Prostate,Neoplasms, Prostatic,Prostate Neoplasms,Prostatic Cancer,Cancer, Prostate,Cancer, Prostatic,Cancers, Prostate,Cancers, Prostatic,Neoplasm, Prostate,Neoplasm, Prostatic,Prostate Cancers,Prostate Neoplasm,Prostatic Cancers,Prostatic Neoplasm
D002352 Carrier Proteins Proteins that bind or transport specific substances in the blood, within the cell, or across cell membranes. Binding Proteins,Carrier Protein,Transport Protein,Transport Proteins,Binding Protein,Protein, Carrier,Proteins, Carrier
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000728 Androgens Compounds that interact with ANDROGEN RECEPTORS in target tissues to bring about the effects similar to those of TESTOSTERONE. Depending on the target tissues, androgenic effects can be on SEX DIFFERENTIATION; male reproductive organs, SPERMATOGENESIS; secondary male SEX CHARACTERISTICS; LIBIDO; development of muscle mass, strength, and power. Androgen,Androgen Receptor Agonist,Androgen Effect,Androgen Effects,Androgen Receptor Agonists,Androgenic Agents,Androgenic Compounds,Agents, Androgenic,Agonist, Androgen Receptor,Agonists, Androgen Receptor,Compounds, Androgenic,Effect, Androgen,Effects, Androgen,Receptor Agonist, Androgen,Receptor Agonists, Androgen
D012738 Sex Hormone-Binding Globulin A glycoprotein migrating as a beta-globulin. Its molecular weight, 52,000 or 95,000-115,000, indicates that it exists as a dimer. The protein binds testosterone, dihydrotestosterone, and estradiol in the plasma. Sex hormone-binding protein has the same amino acid sequence as ANDROGEN-BINDING PROTEIN. They differ by their sites of synthesis and post-translational oligosaccharide modifications. Sex Steroid-Binding Protein,Testosterone-Estradiol Binding Globulin,Binding Globulin, Testosterone-Estradiol,Globulin, Sex Hormone-Binding,Globulin, Testosterone-Estradiol Binding,Hormone-Binding Globulin, Sex,Sex Hormone Binding Globulin,Sex Steroid Binding Protein,Steroid-Binding Protein, Sex,Testosterone Estradiol Binding Globulin

Related Publications

S Scultéty, and J Oszlánczy, and I Faredin, and I Tóth
October 1985, Acta endocrinologica,
S Scultéty, and J Oszlánczy, and I Faredin, and I Tóth
March 1988, Der Urologe. Ausg. A,
S Scultéty, and J Oszlánczy, and I Faredin, and I Tóth
May 1987, The Journal of urology,
S Scultéty, and J Oszlánczy, and I Faredin, and I Tóth
July 1984, The Journal of urology,
S Scultéty, and J Oszlánczy, and I Faredin, and I Tóth
June 1985, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde,
S Scultéty, and J Oszlánczy, and I Faredin, and I Tóth
January 1986, Bulletin du cancer,
S Scultéty, and J Oszlánczy, and I Faredin, and I Tóth
February 1993, Cancer,
S Scultéty, and J Oszlánczy, and I Faredin, and I Tóth
May 1987, The Journal of urology,
S Scultéty, and J Oszlánczy, and I Faredin, and I Tóth
July 1983, The Journal of urology,
S Scultéty, and J Oszlánczy, and I Faredin, and I Tóth
January 1988, American journal of clinical oncology,
Copied contents to your clipboard!